Safety and Efficacy of (90)Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

PURPOSE: We report efficacy and safety of (90)Y-labeled FAPI-46 ((90)Y-FAPI-46-RLT) in patients with advanced sarcoma, pancreatic cancer, and other cancer entities. EXPERIMENTAL DESIGN: Up to four cycles of radioligand therapy (RLT) were offered to patients with (i) progressive metastatic malignancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Fendler, Wolfgang P., Pabst, Kim M., Kessler, Lukas, Fragoso Costa, Pedro, Ferdinandus, Justin, Weber, Manuel, Lippert, Maria, Lueckerath, Katharina, Umutlu, Lale, Kostbade, Karina, Mavroeidi, Ilektra A., Schuler, Martin, Ahrens, Marit, Rischpler, Christoph, Bauer, Sebastian, Herrmann, Ken, Siveke, Jens T., Hamacher, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527500/
https://www.ncbi.nlm.nih.gov/pubmed/35833949
http://dx.doi.org/10.1158/1078-0432.CCR-22-1432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527500/
https://www.ncbi.nlm.nih.gov/pubmed/35833949
http://dx.doi.org/10.1158/1078-0432.CCR-22-1432

Ejemplares similares